Capricor Therapeutics (CAPR) Cash from Operations (2010 - 2026)

Capricor Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 29254891.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 354.73% year-over-year to 29254891.0 in Q1 2026; TTM through Mar 2026 was 92632632.0, a 105.12% decrease from a year earlier, with the FY2025 full-year figure at 69811261.0, down 74.55% from the prior year.
• Cash from Operations slipped to 29254891.0 in Q1 2026 per CAPR's latest filing, from 23566743.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 24046566.0 in Q1 2022 and bottomed at 29254891.0 in Q1 2026.
• The 5-year median for Cash from Operations is 9417750.0 (2023), against an average of 9396576.59.
• Across the five-year window, Cash from Operations surged 822.26% in 2022 and plunged 407.2% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 6902052.0 in 2022, then tumbled by 67.98% to 11594052.0 in 2023, then dropped by 27.62% to 14796329.0 in 2024, then slumped by 59.27% to 23566743.0 in 2025, then dropped by 24.14% to 29254891.0 in 2026.
• Per Business Quant, the three latest CAPR Cash from Operations figures stand at 29254891.0 (Q1 2026), 23566743.0 (Q4 2025), and 19688787.0 (Q3 2025).